-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Obese patients have a higher risk of community-based and in-hospital infections.
, however, there is no study specifically to assess the relationship between obesity and ventilator-associated pneumonia (VAP).
recently published a study in the authoritative journal Chest in the field of respiratory medicine, which aims to explore whether obesity is linked to an increase in vaP incidence.
an ex post-mortem analysis of the NUTRIREA-2 open label RCT, completed in 44 ICUs in France.
researchers included adult patients who received invased mechanical aeration and were treated for shock with vascular pressurization drugs, as well as intestinal or in-intestinal nutrition.
is defined as a body mass index (BMI) of 30 kg/m2 ≥ stay in the ICU.
VAP diagnosis is determined by an independent committee based on all available clinical, imaging and microbiological data.
only consider vaPs that occur for the first time.
used the Fine and Gray models to analyze the occurrence of VAP, using pipe pull and death as competitive risk factors.
699 (30%) of the 2,325 patients were obese.
the study diagnosed 224 first VAPs (60 in the obese and 164 in the non-obese groups, respectively).
the two groups had an 8.6% VS. 10.1% on the 28th day (HR:0.85, 95% CI was 0.63-1.14, p=0.26).
After adjusting for sex, McCabe scores, age, anti-ulcer therapy, and SOFA after random grouping, the occurrence of VAP between obese and non-obese patients remained unstated (HR:0.893, 95% CI 0.66-1.2, p=0.46).
Although there was no significant difference between mechanical breathing time and ICU hospital stay, the 90-day mortality rate was significantly lower for obese patients (272 out of 692 (39.3%) vs. 718 out of 605 (44.7%) patients, p-0.02).
In the subgroup of patients tested for gastric protease and α-amylase (n-123), there was no significant difference in the rate of microsorption or oral secretion of stomach contents between obese and non-obese patients.
obesity had no significant effect on the rate of VAP.
the results of this study show that obesity has no significant effect on the rate of VAP.
